Lupin receives US FDA approval for generic Namenda XR capsules

Memantine hydrochloride extended-release capsules are indicated for treatment of moderate to severe dementia of the Alzheimer’s type

Lupin has recently received final approval for its memantine hydrochloride extended-release capsules, from the US Food and Drug Administration (FDA) to market a generic version of Allergan’s Namenda XR capsules

Lupin’s memantine hydrochloride extended-release capsules, 7 mg, 14 mg, 21 mg, and 28 mg are the AB rated generic equivalent of Allergan’s Namenda XR capsules, 7 mg, 14 mg, 21 mg, and 28 mg. They are indicated for treatment of moderate to severe dementia of the Alzheimer’s type.

EP News Bureau